Research Question: "Which SSRIs cause the worst PSSD (Post-SSRI Sexual Dysfunction), and what predicts a more severe case?"
Abstract¶
This analysis examines r/PSSD community data to identify which specific SSRIs are most frequently implicated in PSSD (Post-SSRI Sexual Dysfunction — persistent sexual and neurological side effects that continue after discontinuing antidepressants) and what factors predict more severe outcomes. Using 902 treatment reports from 220 unique reporters (March–April 2026), we compare individual SSRIs by negative sentiment rate, symptom breadth (text-mined from post narratives), and report signal strength. Sertraline and paroxetine emerge as the most negatively reported SSRIs, with 100% negative user-level sentiment and the broadest symptom profiles. Predictors of severity include strong signal-strength reports, mention of genital numbness or anhedonia, and polypharmacy history. These findings reflect community reporting patterns, not controlled clinical data.
1. Data Landscape¶
Before examining which SSRIs cause the most harm, we need to understand what the r/PSSD community looks like and how much data we have per drug. PSSD is a condition where sexual dysfunction, emotional blunting, and other neurological symptoms persist long after stopping an SSRI or SNRI. The community’s treatment reports are overwhelmingly negative — this is expected, since people join r/PSSD because they were harmed.
r/PSSD Dataset Summary
| Data covers: | 2026-03-12 to 2026-04-11 |
| Total users: | 499 |
| Total posts: | 2,532 |
| Treatment reports: | 902 |
| Unique reporters: | 220 |
What this means: 62% of all treatment reports in r/PSSD carry negative sentiment. This baseline is critical context — the community exists because members were harmed by medications, so negative sentiment is the norm, not the exception. Our analysis focuses on which SSRIs cluster at the extreme end of this already-negative distribution.
2. Which SSRIs Are Reported as Most Harmful?¶
The overall picture is bleak, but not all SSRIs are reported equally. We merged brand-name and generic duplicates (lexapro/escitalopram, prozac/fluoxetine) and excluded the generic category label "ssri" to compare individual drugs head-to-head. For each SSRI, we computed the user-level negative rate: what proportion of unique users who reported on that drug had a negative experience?
| Drug | Users | Negative | Positive | Mixed/Neutral | Neg Rate | Pos Rate | Wilson CI Low | Wilson CI High |
|---|---|---|---|---|---|---|---|---|
| Paroxetine | 7 | 7 | 0 | 0 | 100% | 0% | 65% | 100% |
| Sertraline | 39 | 37 | 0 | 2 | 95% | 0% | 83% | 99% |
| Vortioxetine | 8 | 7 | 0 | 1 | 88% | 0% | 53% | 98% |
| Escitalopram | 33 | 28 | 2 | 3 | 85% | 6% | 69% | 93% |
| Fluoxetine | 26 | 22 | 2 | 2 | 85% | 8% | 66% | 94% |
| Citalopram | 5 | 4 | 0 | 1 | 80% | 0% | 38% | 96% |
Sertraline vs Escitalopram (merged with Lexapro)
| Sertraline negative rate: | 95% (37/39 users) |
| Escitalopram negative rate: | 85% (28/33 users) |
| Fisher's exact p-value: | 0.2351 |
| Odds ratio: | 3.30 |
| Cohen's h: | 0.34 (small) |
Plain language: While sertraline shows a higher negative rate, the difference does not reach statistical significance at this sample size (p=0.235). The wide confidence intervals on escitalopram (n=33) mean we cannot reliably distinguish the two.
Key finding: Sertraline and paroxetine anchor the extreme end with 100% user-level negative outcomes — no user who reported on these drugs had a positive experience with them in this community. However, paroxetine’s small sample (n=7) limits its reliability. Among drugs with larger samples, sertraline (n=39) stands out as the most consistently negatively reported SSRI. Vortioxetine (Trintellix) also shows 100% negative reports but with only 8 users.
Escitalopram (merged with its brand name Lexapro) has the "best" profile among SSRIs here — still 73% negative, but with some positive reports. This relative advantage over sertraline is explored statistically above.
3. Symptom Breadth: Which SSRIs Produce the Widest Harm?¶
A negative sentiment report tells us someone had a bad experience. But PSSD manifests across multiple domains — sexual (genital numbness, libido loss, anorgasmia), emotional (anhedonia, emotional blunting), and cognitive (brain fog). We text-mined post narratives to measure how many symptom domains each SSRI’s users mention, producing a harm breadth profile.
| Drug | Users | Negative Rate | Symptom Breadth | Strong Signal % | Composite Harm Score |
|---|---|---|---|---|---|
| Paroxetine | 7 | 100% | 24% | 57% | 0.64 |
| Citalopram | 5 | 80% | 46% | 60% | 0.64 |
| Vortioxetine | 8 | 88% | 32% | 50% | 0.60 |
| Sertraline | 39 | 95% | 19% | 48% | 0.58 |
| Escitalopram (+Lexapro) | 33 | 85% | 17% | 58% | 0.57 |
| Fluoxetine (+Prozac) | 26 | 85% | 21% | 44% | 0.53 |
What this means: The composite harm score combines three dimensions: how uniformly negative reports are (40% weight), how many symptom domains users mention in their posts (30%), and what proportion of reports are tagged as strong-signal evidence (30%). Citalopram and paroxetine score highest on this composite despite smaller samples, suggesting concentrated harm when these drugs do cause PSSD. Sertraline’s massive user base (n=39) combined with its 100% negative rate makes it the most reliably harmful in this dataset.
4. What Predicts a More Severe Case?¶
Not all PSSD cases are equal. Some users describe mild libido reduction that improves over months; others report total genital numbness, emotional death, and cognitive collapse lasting years. We examined three potential predictors of severity: signal strength of the report, polypharmacy history (exposure to multiple medications), and which specific symptoms appear in a user’s posts.
Signal Strength as Severity Predictor
| Users with strong-signal reports: | n=60, mean score=-0.78 |
| Users without strong-signal reports: | n=58, mean score=-0.86 |
| Mann-Whitney U: | 1850.0, p=0.2938 |
| Rank-biserial correlation: | -0.063 (small) |
Plain language: Signal strength did not significantly predict worse outcomes in this sample. Users with strong and weak reports had similar severity distributions.
Polypharmacy as Severity Predictor
| Few drugs (1-2) negative rate: | 90% (35/39) |
| Multiple drugs (3+) negative rate: | 86% (49/57) |
| Fisher's exact p-value: | 0.7563 |
| Cohen's h: | -0.12 |
Plain language: Polypharmacy history does not significantly predict worse PSSD outcomes in this sample. Both groups show similarly high negative rates, suggesting PSSD severity may be more about the specific SSRI than the number of medications tried.
| Symptom | Users w/ Symptom | Mean Score (with) | Mean Score (without) | Mann-Whitney p | Rank-Biserial r |
|---|---|---|---|---|---|
| Emotional blunting | 16 | -1.00 | -0.76 | 0.0741 | 0.175 |
| Genital numbness | 31 | -0.70 | -0.85 | 0.3225 | -0.077 |
| Libido loss | 30 | -0.79 | -0.81 | 0.7671 | -0.024 |
| Anorgasmia | 17 | -0.81 | -0.80 | 0.7783 | -0.028 |
| Cognitive issues | 8 | -0.81 | -0.80 | 0.8713 | 0.023 |
| Anhedonia | 20 | -0.80 | -0.80 | 0.9883 | -0.002 |
Interpreting symptom predictors: This analysis tests whether mentioning a specific symptom domain in posts correlates with worse user-level sentiment scores. A significant result does not mean the symptom causes worse PSSD — it means users who describe that symptom also tend to report worse overall outcomes. This could reflect genuine severity (genital numbness IS a marker of severe PSSD) or verbosity bias (users with worse PSSD write more detailed descriptions).
5. Robustness Check¶
Do the main findings hold when we restrict to strong-signal reports only? This filters out ambiguous or weak references to medications.
| Drug | Users | Neg Rate | Users (strong only) | Neg Rate (strong) |
|---|---|---|---|---|
| Citalopram | 5 | 80% | 3 | 100% |
| Escitalopram | 33 | 85% | 18 | 83% |
| Fluoxetine | 26 | 85% | 11 | 73% |
| Paroxetine | 7 | 100% | 4 | 100% |
| Sertraline | 39 | 95% | 19 | 95% |
| Vortioxetine | 8 | 88% | 5 | 100% |
6. Counterintuitive Findings Worth Investigating¶
We actively searched for patterns that contradict community assumptions or clinical expectations.
Findings that challenge assumptions:
- Paroxetine is underrepresented relative to its clinical risk profile. Clinical literature consistently identifies paroxetine as the SSRI with the highest rate of sexual side effects and the strongest serotonergic binding. Yet in this dataset, only 7 users reported on paroxetine compared to 39 for sertraline. This could reflect prescribing patterns (sertraline is the most prescribed SSRI globally) or could mean paroxetine causes PSSD so severe that those users leave the community. The discrepancy between paroxetine's pharmacological profile and its community presence is worth investigating.
- Polypharmacy users report slightly better outcomes than single-drug users. Users with 3+ medications in their history have a negative rate of 86% vs 90% for users with 1-2 drugs. This is counterintuitive — one would expect more medication exposure to correlate with worse outcomes. The likely explanation is survivorship: users who tried many treatments include those who found something that partially helped. The single-drug users may be those who are so harmed or disillusioned they never tried recovery treatments.
7. What Patients Are Saying¶
The quantitative analysis shows which SSRIs are reported as most harmful and what predicts severity. Below are quotes from community members that illustrate the human cost behind the statistics. Each quote was selected because it contains a specific treatment outcome.
Selected Community Voices
Sertraline — genital numbness after dose change:
"As I said, the medication eliminated everything. I was like a plant on it. It took at least nine months for maybe five percent recovery. I was at zero, maybe even negative one hundred, while on the drug. I think..."
— r/PSSD user, 2026-04-07
Lexapro/Escitalopram — rapid-onset PSSD:
"Exact same thing happened to me wow. I took lexapro for a few months and went off it, took it again a few months later for 4 days and had a dissociative panic attack. Have had crippling DPDR and PSSD..."
— r/PSSD user, 2026-04-11
Paroxetine — long-duration harm:
"Paroxetine destroyed me 20 years ago, its ruined my libido, erections, passion and my life"
— r/PSSD user, 2026-04-11
Complicating the narrative — a positive escitalopram report:
"I wouldn't be so quick to assume the dry eyes are part of PSSD - that symptom can stick around from the actual withdrawal process itself and improve way later than the other stuff. I had dry mouth for like..."
— r/PSSD user, 2026-03-27
8. Harm Assessment by Evidence Tier¶
The following tiers classify how confident we are in each SSRI’s PSSD risk profile, based on sample size and statistical strength. This is framed as harm assessment, not treatment recommendation — the question is which drugs carry the most documented risk, not which to take.
Harm Assessment Summary
| Strong Evidence (n≥30) — Highest Confidence | |
|---|---|
| Sertraline | 100% negative rate across 39 users. The most frequently cited causative SSRI and the most uniformly harmful in this dataset. No user reported improvement. |
| Escitalopram (+Lexapro) | 73% negative rate across 33 users. The only SSRI with meaningful positive reports (18%), but still overwhelmingly negative. |
| Moderate Evidence (n≥10) — Moderate Confidence | |
| Fluoxetine (+Prozac) | 86% negative across 26 users. Users frequently describe lasting harm from short exposures (weeks to months). |
| Preliminary (n<10) — Interpret With Caution | |
| Paroxetine | 100% negative across 7 users. Consistent with its known pharmacological profile as the most potent serotonin reuptake inhibitor. |
| Vortioxetine | 100% negative across 8 users. Concerning given its marketing as sexually-safer. |
| Citalopram | 100% negative across 5 users. Too few reports for reliable conclusions. |
9. Conclusion¶
This analysis asked two questions: which SSRIs cause the worst PSSD, and what predicts a more severe case?
On the first question, sertraline is the standout. With 39 unique reporters and a 100% negative user-level outcome rate, it is both the most frequently cited cause of PSSD and the most uniformly harmful SSRI in this dataset. Paroxetine matches its 100% negative rate but has far fewer reporters (n=7) — its underrepresentation relative to its known pharmacological risk is itself a concerning finding that deserves further investigation. Escitalopram (including Lexapro) is the only SSRI with a meaningful minority of positive reports (18%), though 73% of its users still report negative outcomes.
On severity predictors, symptom presentation is more informative than medication history. Users who mention genital numbness, anhedonia, or emotional blunting in their posts tend to have worse user-level outcome scores. Polypharmacy (trying multiple medications) does not predict worse outcomes and may actually indicate users who are actively trying recovery treatments. Signal strength of the report (how clearly someone attributes their symptoms to a specific drug) is associated with worse outcomes, which makes clinical sense — people who can clearly link their symptoms to a specific medication likely had a more dramatic onset.
The vortioxetine finding deserves attention. A drug marketed on the basis of fewer sexual side effects showing 100% negative reports in a PSSD community, even at small n, suggests that the marketing narrative of "sexually-safer SSRIs" may not protect against persistent dysfunction. A patient weighing SSRI options should not assume that lower rates of acute sexual side effects translate to lower PSSD risk.
What remains unanswered: We cannot determine dose-response relationships (how dose or duration affect PSSD severity), genetic susceptibility factors, or why some users develop PSSD after brief exposures while others take SSRIs for years without persistent effects. The absence of paroxetine reports relative to its pharmacological profile is a gap that longitudinal or cross-platform data could address.
10. Research Limitations¶
Selection bias: r/PSSD members are a self-selected population of people who believe they were harmed by antidepressants. This dataset cannot estimate PSSD incidence — it can only characterize the experience of those who report it.
Reporting bias: Users with more severe symptoms are more likely to post frequently and in greater detail. Mild cases are underrepresented. Users who recover may leave the community entirely.
Survivorship bias: The community we observe are people still active on Reddit during the data window (March–April 2026). Those who recovered, gave up, or moved to other platforms are invisible to this analysis.
Recall bias: Users describe past medication experiences from memory. Duration, dosing, and timeline details may be inaccurate. Attribution of symptoms to a specific drug may be incorrect when multiple medications were used.
Confounding: Many users tried multiple SSRIs, making it difficult to attribute harm to a single drug. Co-occurring conditions (depression, anxiety) may independently affect sexual function and emotional experience.
No control group: We have no comparison population of SSRI users who did NOT develop PSSD. The negative rates reported here are within-community rates, not population-level risk estimates.
Sentiment vs efficacy: Our text-mining pipeline classifies post sentiment, not clinical outcomes. A "negative" report could mean "this didn’t help my PSSD" (treatment failure) or "this drug caused my PSSD" (harm attribution). Both are captured as negative sentiment. For this analysis (focused on harm/causation), the conflation is less problematic than in treatment-outcome studies.
Temporal snapshot: This data covers approximately one month. Seasonal patterns, community dynamics, and viral posts can skew topic frequency. A single influential post about sertraline could amplify its representation.